The genetic predisposition of hypouricemia 
Introduction
Uric acid (UA) is the final product of purine metabolism in humans 1 . After reuptake in the renal proximal tubule, only 10% of filtered UA is eliminated in the urine 2 . Serum UA level is determined by the balance between the rate of purine metabolism and clearance. Hypouricemia can be caused by malnutrition or genetic predisposition. The forms of genetic predisposition can be classified as a functional disability in UA synthesis and defects in the UA reabsorption system. Deficiencies of xanthine oxidase (XO), purine nucleoside phosphorylase (PNP), and 5-phosphoribosyl-pyrophosphate (PRPP) are related to the defects in UA synthesis 3 . Inherited disorders of UA metabolism present as serious conditions such as intellectual disability or immunodeficiency. Renal hypouricemia (RHUC) is asymptomatic and its identification is difficult in primary medical practice unless they were presented as renal stone or exercised induced acute renal failure. The main cause is a defect in the UA reabsorption system. RHUC is a rare inherited disorder involving multiple renal UA transporters 2 . Two types are currently reported: Type 1(OMIM: 220150) and Type 2 (OMIM: 612076). These genetically deleterious forms were identified as case reports of exerciseinduced acute kidney injury (EIAKI), renal failure, and nephrolithiasis. Currently, diagnosis is based on hypouricemia (<2 mg/dL) and increased fractional excretion of UA (>10%) 4 .
RHUC was first reported in Japan, and a mutation was found in the gene of a drug transporter in the renal proximal tubule 5, 6 . Recently, various ethnic groups including Israeli-Arab, Iraqi-Jewish, and Roma populations in the Czech Republic and Slovakia have reported renal hypouricemia [7] [8] [9] [10] [11] [12] and have been added (https://genome.ucsc.edu/). Given the role of the nitrogen excretion function in the evolutionary process, we identified amino acid sequences in several mammals (Rhesus macaque, Mus musculus, Canis lupus familiaris, and Loxodonta africana) that share the urea cycle rather than direct UA excretion. Third, the prediction of the functional effect of variants was performed using the latest version of PolyPhen-2, SIFT, Condel, and Mutation Taster algorithms [24] [25] [26] [27] .
In silico prediction of molecular dynamics
We initially predicted the structure of SLC22A12 and SLC2A9 using a homology modeling program, SWISS-MODEL (https://swissmodel.expasy.org/). The quality of predicted 3D structures was estimated on the basis of the geometrical analysis of the single model, global model quality estimation (GMQE) score and qualitative model energy analysis (QMEAN) 28 . The GenBank accession number used for each amino acid sequence was NP_653186 for SLC22A12 and NP_064425 for SLC2A9. After homology modeling was completed, we selected a suitable X-ray structure for SLC22A12 (PDB ID: 4ZW9, SLC2A3) and SLC2A9
(PDB ID: 4YBQ, SLC2A5) 29, 30 . For the more stable molecular dynamics simulations, we used I-Tasser generated models 31 . All models were generated and made publicly available and can be recovered together with the statistics from the server site (https://zhanglab.ccmb.med.umich.edu/I-TASSER/about.html). All graphical representations are made using the initial I-Tasser generated models to aid reproducibility. A qualitative evaluation of the mutation effect was evaluated based on four simple criteria. Binding urate (U) and the p.Arg284Gln mutation, were identified as compound heterozygous (NIH17A8798528). Finally, it was also confirmed that the novel p.Asn136Lys mutation was heterozygous with a previously reported p.Leu418Arg mutation (NIH17K4930892) ( Table 2) . Detailed properties of the four mutations on SLC22A12 and one mutation on SLC2A9 are shown in Table 2 and Table 3 . The overall distribution of allele frequencies of SLC22A12 variants, which are previously reported in HGMD or are newly discovered, is shown in Figure 2 . The novel SLC22A12 and SLC2A9 variants were confirmed in the participant DNA samples by direct Sanger sequencing (Figure 3) . We used several methods for the functional prediction of the three SLC22A12 variants and one SLC2A9 variant found above. Amino acid sequence conservation was compared with R. macaque, M. musculus, C. lupus familiaris, and L. africana ( Table 3 ). All four prediction tools (Mutation Taster, Polyphen2, SIFT, Condel) indicated that the two SLC22A12 variants (p.Thr225Lys, p.Arg284Gln) were found to be deleterious for the function of the encoded proteins in NIH17A8798528.
p.Glu429Lys of SLC22A12 found in NIH17A8865148 was only predicted to be disease-causing in Mutation
Taster, whereas it was predicted to be benign in the remaining tools. In the case of p.Asn136Lys, however, all prediction tools indicated that this amino acid change was not deleterious. No prediction result was obtained for p.Met155Val of SLC2A9 found in NIH17A8568242 (Table 3) .
Molecular dynamic prediction of SLC22A12 and SLC2A9 and novel variant location
The amino acid substitutions in SLC22A12 (10 mutations) and SLC2A9 (2 mutations) were considered.
The predicted functional impact of the amino acid change is illustrated in Table 5 . Our overall organization of SLC2A9 and SLC22A12 is similar to the molecular dynamics approach described by Clemencon et al. 35 .
Steered dynamic simulations of urate transport were performed with mutations in SLC22A12 and SLC2A9
and are presented in Figure 4 . Assessing the extent of the effect of the mutations in the S set is difficult in a qualitative analysis due to the large changes observed during the molecular dynamics trajectory. p.Arg90His, 
Discussion
In this study, we comprehensively evaluated the contribution of genetic predisposition to hypouricemia with WES data and genotyping date in 81 unrelated patients. Our approach is derived from that of the previous population-based studies on the adverse health effects of hypouricemia 20, 36 . Throughout our study, we were able to evaluate the genetic markers in hypouricemia which could have a potential diagnostic role for the first time. Of the 34 patients whose WES data were available, 27 had bi-allelic exonic variants within SLC22A12 and one had a compound heterozygous variant in SLC2A9. We discovered four novel mutations in SLC22A12 and one mutation in SLC2A9 and identified the novel candidate genes in the recessive trait ( For six unexplained cases, novel candidate genes were identified using the WES analysis strategy described above ( Table 4, Supplementary table 4) . In a systematic review, most of the genes are not known to be involved in biological pathways affecting UA levels. However, the p.Arg78His variant (rs145118752) of ASB12 on chromosome X, which was discovered in both NIH17A8004492 and YID182829, is found in 0.018% of the whole population and 0.16% when limited to East Asia only (gnomAD 2018.7, http://gnomad.broadinstitute.org/). Thus, the fact that the rare variant was shared in unrelated hypouricemic individuals indicates that there is a considerable possibility of disease-causing potential in this variant. Little is known about the functional significance of this gene. Since it is postulated that the ASB family may be involved in protein degradation via mediating the ubiquitin-proteasome system or signal transduction 50 , it may be involved in trafficking or the intracellular degradation of the UA transporter. Further studies are needed to elucidate the association between hypouricemia and the ASB12 variant and this is the limitation of study that six unexplained cases are not clearly explained in relation to a significant decrease in serum UA levels. Family study with unsolved cases of SLC22A12 and SLC2A9 would be beneficial to reach more definite conclusions on the segregation patterns of variants. Given that several causative genes for hypouricemia are still unidentified, genetic inheritance of hypouricemia could be more common than indicated by our results.
The main purpose of this study was to view the composition of known and unknown genes for RHUC systematically in a population-based study. Hypouricemia is often regarded as an unrecognized or neglected disorder in a public health aspect. The prevalence of urolithiasis through excess UA excretion is 6-7 times higher in patients with RHUC than in the normal population 34 . Reflecting the ability of UA as a powerful scavenger of peroxide radicals, accounting for up to 60% in the plasma, evidence of oxidative stress has accumulated not only in EIAKI and urolithiasis but also in neurodegenerative disease (Parkinson's disease) [51] [52] [53] [54] [55] . The anti-oxidative stress hypothesis is also supported by the results of Facheris et al., which show that the SLC2A9 mutation is associated with lower serum UA and increased early onset of Parkinson's disease 56 .
Early identification and intervention of hypouricemia (avoiding hard exercise, drinking plenty of water, and pre-emptively taking XO inhibitors) may prevent its adverse outcome in the near future, especially military personnel and athletics. XO inhibitor use (allopurinol or febuxostat) may be beneficial by lowering filtered UA. Neonatal screening or in-born screening of two SNPs (p.Trp258*/rs121907892 and p.Arg90His/rs121907896) will help in the early diagnosis of hypouricemia and increase awareness among primary care physicians or medical care professionals in army to prevent it from progressing to adverse outcomes. Since the genotyping of two SNPs costs less than 5 dollars and requires only half a day, it will be a huge advantage for medical doctors to consider this genetic test as a routine procedure. Our findings of 87.7% of patients with hypouricemia explained by two SNPs in SLC22A12 gives strong evidence for its feasibility in diagnostic use. Our findings indicate that the genotyping of two SNPs in SLC22A12 followed by WES is a simple and precise protocol for molecular diagnosis of sporadic cases of hypouricemia complicated by renal stones or EIAKI.
In summary, this study indicates the value of genetic screening of hypouricemia and suggests close monitoring of UA levels to prevent not only urolithiasis but also oxidative stress-induced disease progression for hypouricemia patients in the primary care setting. 
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